The Neurotrauma Assessment Test (NAT) is a highly-sensitive assessment that detects the presence of proteins that are released when the brain and or spinal cord are injured. These proteins are often referred to as biomarkers. Biomarkers (such as GFAP) are released into the blood after brain injury and are used as an indicator of the severity of the injury. While these biomarkers are typically elevated in the blood immediately after injury, they can also be detected in the blood months after the injury has occurred.
TBI biomarkers can provide important information about the amount of injury to the brain, but they are just one tool used to assess the severity of a TBI. Other diagnostic tests, such as CT scans or MRIs, may also be needed to fully evaluate the extent of the brain injury.
Neurotrauma Assessment Test
This blood test can provide information about the type and amount of brain injury, and can help
predict outcomes and guide treatment decisions. The use of blood tests for TBI biomarkers is an area of active research, and new biomarkers are being identified and evaluated. As our understanding of TBI and the role of biomarkers in its diagnosis and management continues to evolve, blood tests will become increasingly important tools in the assessment of TBI.s
